Pulmonary embolism (PE) is treated primarily with blood thinners, which remain the cornerstone of care for the vast majority of patients. More severe cases may require clot-dissolving drugs, catheter-based procedures, or surgery. The specific treatment depends on how much the clot is straining your heart and lungs, which doctors assess within the first hours of diagnosis.
How Severity Determines Your Treatment
Not every PE is a medical emergency requiring hospitalization. The latest guidelines from the American Heart Association and American College of Cardiology classify PE into five categories (A through E) based on symptoms, blood pressure, heart strain, and lab markers. This classification drives every treatment decision that follows.
If you have a PE but no symptoms (Category A), you can often be sent home from the emergency room with a prescription for blood thinners. Patients with mild symptoms and low risk scores (Category B) are also generally candidates for early discharge. Once there are signs of heart strain, such as elevated cardiac biomarkers or the right side of the heart working harder than normal (Category C), hospitalization becomes necessary. The most dangerous presentations involve impending or active cardiovascular collapse (Categories D and E), where blood pressure drops below 90 mmHg or you need medication to maintain it. These patients require intensive care and often advanced interventions beyond blood thinners alone.
Blood Thinners: The Foundation of Treatment
Almost everyone diagnosed with PE starts on anticoagulant therapy, commonly called blood thinners. These medications don’t dissolve the existing clot. Instead, they stop it from growing and prevent new clots from forming, giving your body time to break down the blockage naturally.
Current guidelines recommend direct oral anticoagulants (DOACs) over older options like warfarin for most patients. DOACs work predictably without requiring frequent blood tests or dietary restrictions, and they carry a lower risk of major bleeding. For patients who need an injectable blood thinner first, low-molecular-weight heparin (injected under the skin) is preferred over the intravenous form, which requires closer monitoring in the hospital.
The minimum treatment duration is 3 to 6 months. After that, whether you continue depends on what caused the clot. If your PE was triggered by a clear, temporary risk factor, like surgery, a broken bone, or a long period of immobility, you can typically stop after the initial course. But if there was no obvious trigger (called an “unprovoked” PE) or if you have an ongoing risk factor such as cancer or a clotting disorder, guidelines recommend continuing anticoagulation indefinitely. Your doctor will weigh the risk of a recurrent clot against the ongoing bleeding risk to make this decision with you.
Clot-Dissolving Therapy for Severe Cases
When a PE causes dangerously low blood pressure or cardiovascular collapse, blood thinners alone aren’t fast enough. Systemic thrombolysis uses powerful clot-dissolving drugs delivered through an IV to rapidly break up the blockage and restore blood flow through the lungs. This is the most aggressive medical therapy available and is reserved for the most life-threatening situations.
The trade-off is a significant risk of serious bleeding. Several conditions make thrombolysis too dangerous to attempt: a history of bleeding in the brain, a stroke within the past three months, active bleeding anywhere in the body, recent brain or spinal surgery, and certain bleeding disorders. For patients with these contraindications, catheter-based or surgical options become the alternatives.
In some intermediate-risk patients who are technically stable but showing signs of deterioration, such as worsening heart strain or poor organ function, thrombolysis may also be considered before the situation becomes critical.
Catheter-Based Procedures
Catheter-based treatments sit between blood thinners and open surgery on the intervention spectrum. A thin tube is threaded through a vein, usually starting in the groin, and guided into the pulmonary arteries where the clot is lodged. Several techniques exist, and they can be used alone or in combination.
Aspiration embolectomy uses large-bore catheters to physically suction clot material out of the artery. Systems like the FlowTriever use catheters ranging from 16 to 24 French (roughly 5 to 8 mm in diameter) along with self-expanding mesh discs that can engage clots in vessels of various sizes. Another approach, the Indigo system, uses a pump to create negative pressure and a wire to break up clot material while it’s being aspirated.
Ultrasound-assisted thrombolysis delivers clot-dissolving medication directly to the blockage through a specialized catheter while emitting ultrasound waves. The ultrasound loosens the fibrin structure of the clot, allowing the medication to penetrate more deeply. This approach uses far less clot-dissolving drug than systemic thrombolysis (typically 4 to 24 mg compared to a full systemic dose), which lowers the bleeding risk while still targeting the clot effectively.
Mechanical fragmentation, the simplest catheter technique, uses a rotating catheter tip to physically break the clot into smaller pieces. This redistributes the blockage across a wider area of the lung’s blood vessels, which can improve blood flow enough to stabilize a patient. It carries some risk of sending fragments deeper into smaller vessels, but the technique is widely available and technically straightforward.
Surgical Embolectomy
Open surgery to physically remove clot from the pulmonary arteries is the most invasive option and is reserved for specific scenarios: massive, centrally located clots when clot-dissolving drugs are too risky or have already failed, when a clot is caught in transit through the heart, or when there is a large hole between the heart’s upper chambers that could allow a clot to cross to the brain.
Surgical embolectomy has become substantially safer over the past few decades. Mortality rates that once exceeded 30% have dropped to between 3.6% and 13% in modern series. In one study of 115 patients, overall surgical mortality was 6.6%, and among the subgroup with intermediate-risk PE, it was just 3.6%. One-year survival rates in recent reports reach 86%. These improvements reflect better patient selection, surgical technique, and post-operative care, but the procedure still carries meaningful risk and remains a last-resort option for most patients.
IVC Filters
An inferior vena cava (IVC) filter is a small, cage-like device placed in the large vein that carries blood from the lower body to the heart. It catches clots traveling up from the legs before they can reach the lungs. The only widely agreed-upon reason to place one is when a patient has an acute blood clot but cannot safely take blood thinners, for example, because of active major bleeding. Retrievable filters are strongly preferred over permanent ones, since most patients eventually become able to take anticoagulants again.
IVC filters are not recommended as a preventive measure in high-risk patients (such as those undergoing trauma surgery, bariatric surgery, or hip and knee replacements) and are not recommended for routine use alongside blood thinners. Studies have not shown a benefit from adding a filter when anticoagulation is already being given.
Recovery and Returning to Activity
Most people can walk and do light household tasks right after a PE diagnosis, as long as shortness of breath allows it. If breathing is significantly limited or painful, it’s reasonable to rest more in the early days.
For more vigorous exercise, the general recommendation is to avoid athletic activities for the first 10 to 14 days. During this window, the clot is still becoming more firmly attached to the vessel wall, and intense exertion could theoretically dislodge it. You can stay active during this period with gentle strength training that doesn’t heavily tax your cardiopulmonary system. Between weeks two and four, you can gradually increase intensity, with a realistic goal of returning to your pre-PE activity level by around week four if your body tolerates it. Extreme body positions, like those in certain yoga poses, are best avoided for the first four weeks.
Long-Term Monitoring After PE
Between 1% and 5% of PE survivors develop a chronic condition where organized scar tissue from the original clot permanently narrows the pulmonary arteries, leading to a form of high blood pressure in the lungs called chronic thromboembolic pulmonary hypertension (CTEPH). Symptoms include persistent shortness of breath, exercise intolerance, and fatigue that don’t improve even after the initial treatment period.
Because CTEPH can develop months after the original event, guidelines recommend that your care team ask about breathing symptoms and exercise limitations at every follow-up visit for at least one year. If your shortness of breath isn’t improving or is getting worse several months into treatment, it’s worth raising with your doctor rather than assuming it’s just slow recovery. CTEPH is treatable when caught, but it requires specialized evaluation.